I don't know how to prove it, but suspect that much of the money coming out of SGEN is coming into IMGN. Barring a new drug approval before the next drug from IMGN or it's partners is approved, I believe that we could exceed their market cap after another approval.
By the end of this year, barring something that's really very positive from SGEN, I believe that the progress that IMGN's making will see our market cap growing to at least half of their market cap, which could be substantially lower than it is today.
Gary